Skip to main content

Table 1 Demographics, clinical features, treatments and outcomes

From: Clinical outcomes following intravitreal methotrexate for primary vitreoretinal lymphoma

Patient

Age/sex

Affected eye

CNS disease

Systemic treatment

PVRL location

Initial VA

Final VA

Total # MTX

Time to response (months)

Time to relapse (months)

PVRL status at final FU

Total FU (months)

1

57/F

OD

Frontal lobe DLBCL s/p resection

MTX, RIT

VIT

20/20

20/50

4

0.25

CR

33

  

OS

  

VIT/SR

20/30

20/70

9**

0.25

14

CR

33

2

72/F

OS

CNS DLBCL

MTX

VIT/SR

20/1000

20/40

8

2.0

PR

20

3

69/F

OS

R Parietal DLBCL

MTX

VIT

20/60

20/30

5*

1.6

5

CR

19

4

66/F

OS

R cerebellar DLBCL

MTX, RIT, TMZ

SR

20/60

20/40

1

1.2

CR

14

5

58/F

OD

Frontal lobe DLBCL

MTX

VIT

20/25

20/20

3

2.8

CR

3

  

OS

  

SR

20/20

20/20

3

4.2

CR

4

6

86/F

OS

None

None

SR

20/20

20/40

2

2.8

CR

49

7

84/M

OD

DLBCL

MTX

SR

20/70

20/150

10*

2.6

2.6

PR

44

  

OS

  

VIT/SR†,‡

20/30

20/50

6*

1.1

3.9

CR

44

  1. PVRL Primary vitreoretinal lymphoma, VA Visual acuity, F Female, M Male, OD Right eye, OS Left eye, DLBCL Diffuse large B-cell lymphoma, MTX Methotrexate, RIT Rituximab, TMZ Temozolamide, VIT Vitreous, SR Subretinal/Retinal pigment epithelial disease, FU Follow-up, CR Complete response, PR Partial response
  2. Patient 7 presented initially with vitreous involvement OS, and developed subretinal/RPE disease at the time of relapse
  3. Patient 7 also had a history of wet age-related macular degeneration requiring multiple bevacizumab and aflibercept injections during the disease course
  4. *2 total cycles of intravitreal MTX due to relapse, **3 cycles of intravitreal MTX due to 2 relapses OS